Exhibit 99.1 PHILADELPHIA, Aug. 14, 2025 -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the first half of 2025, we made important business decisions to ensure our capital resource allocation and pipeline development activities are centered on poten ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR For the transition period from _____to _____ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40261 Soluna Holdings, Inc. (Exact name of registrant as specified in its charter) __________________ Nevada 14-1462255 State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-40261 Soluna Holdings, Inc. (Exact name of registrant as specified in its charter) __________________ Nevada 14-1462255 State or ...

LITTLE ROCK, Ark. (GLOBE NEWSWIRE) – August 14, 2025 - Dillard's, Inc. (NYSE: DDS) (the "Company" or "Dillard's") announced operating results for the 13 and 26 weeks ended August 2, 2025. This release contains certain forward-looking statements. Please refer to the Company's cautionary statements included below under "Forward-Looking Information." Dillard's Chief Executive Officer William T. Dillard, II commented on the quarter, "We were happy to achieve a sales increase for the first time in a while and en ...

U. S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number 001-38182 BEELINE HOLDINGS, INC. (Name of small business issuer as specified in its charter) (State or other jurisdiction of inco ...

IQST - IQSTEL Reports Q2 2025 Results – $17.41 Assets per Share, Beating Several Metrics Including Net Shareholders' Equity, Gross Revenue, Gross Margin, Net Income, and Adjusted EBITDA of the Operating Business, Alongside Strong Equity Growth, Margin Expansion, and Rising Profitability The company is evolving from a Telecom and Technology business into a Global Connectivity & AI Technology Corporation New York, NY – Aug. 14, 2025 – IQSTEL Inc. (NASDAQ: IQST) today announced its financial results for the se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36259 NOVA LIFESTYLE, INC. (Exact name of registrant as specified in its charter) Nevada 90-0746568 (State or other jurisdiction of incorporation or organization) 6565 E. Wa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ (877) 848-8430 (Address including zip code, and telephone number including area code, of registrant's principal ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to ___________ Commission File Number: 001-41154 SIDUS SPACE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-0628183 FORM 10-Q (Mark One) 150 N. Syk ...

[Business Transition and Strategy](index=1&type=section&id=Business%20Transition%20and%20Strategy) Applied DNA transitioned to a pure-play synthetic DNA and mRNA solutions provider, focusing on LineaDNA™, LineaRNAP™, and LineaIVT™ - The company has transitioned to a pure-play provider of synthetic DNA and mRNA manufacturing solutions for advanced biotherapeutics and diagnostics[3](index=3&type=chunk) - Commercialization efforts focus on LineaDNA™ (cell-free DNA production), LineaRNAP™ (next-gen T7 RNA polymerase), and LineaIVT™ (an integrated system combining both)[3](index=3&type=chunk) [Management Commentary](index=2&type=section&id=Management%20Commentary) Management confirms operations align with core cell-free DNA and mRNA manufacturing, focusing on shareholder value - Management confirms the company is repositioned as a single business focused on its core competencies in cell-free DNA and mRNA manufacturing solutions[4](index=4&type=chunk) - The company is actively marketing its offerings under the LineaRx brand to deliver value to shareholders[4](index=4&type=chunk) [Recent Corporate and Operational Updates](index=2&type=section&id=Recent%20Corporate%20and%20Operational%20Updates) The company achieved significant operational progress, including reduced cash burn and key commercial milestones - Monthly net cash burn from operations declined approximately **19% sequentially** and **25% year-over-year** due to cost-cutting initiatives[5](index=5&type=chunk) - Received a multi-gram follow-on order for LineaDNA valued at over **$600 thousand** from a global manufacturer of IVDs for a cancer diagnostic application[8](index=8&type=chunk) - Acquired a U.S.-based mRNA contract development manufacturing organization (CDMO) as a new customer for LineaDNA IVT templates[8](index=8&type=chunk) - Launched the LineaRx IVT Discovery Kit to facilitate customer evaluation and initiated industry marketing for LineaRNAP as a standalone product[8](index=8&type=chunk) - Initiated ISO 13485 certification, an international quality management standard, with expected completion in the first quarter of fiscal 2026[13](index=13&type=chunk) [Third Quarter Fiscal 2025 Financial Highlights](index=3&type=section&id=Third%20Quarter%20Fiscal%202025%20Financial%20Highlights) Q3 FY2025 highlights include **$304 thousand** revenue, **$3.7 million** operating loss, and **$4.7 million** cash Q3 FY2025 Key Financial Metrics (vs. Q3 FY2024) | Metric | Q3 FY2025 ($) | Q3 FY2024 ($) | | :--- | :--- | :--- | | Total Revenues | $304 thousand | $473 thousand | | Operating Loss | $3.7 million | $3.3 million | | Adjusted EBITDA | ($3.9 million) | ($3.2 million) | Cash Position and Burn Rate | Metric | Amount ($) | | :--- | :--- | | Cash and Cash Equivalents (as of June 30, 2025) | $4.7 million | | Monthly Net Cash Burn (Q3 FY2025) | $934 thousand | - The company executed two reverse stock splits: a **1-for-50** effective March 14, 2025, and a **1-for-15** effective June 2, 2025[11](index=11&type=chunk) - Financial results have been recast to report the closed MDx Testing Services business as discontinued operations, with the DNA Tagging segment wind-down included in continuing operations[9](index=9&type=chunk)[10](index=10&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) This section presents unaudited condensed consolidated financial statements and Adjusted EBITDA reconciliation [Condensed Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, total assets were **$9.9 million**, cash **$4.7 million**, and liabilities **$2.9 million** Balance Sheet Summary (as of June 30, 2025) | Account | June 30, 2025 ($) | September 30, 2024 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | $4,727,677 | $5,852,363 | | Total current assets | $5,628,902 | $8,047,671 | | Total assets | $9,934,746 | $12,789,040 | | Total current liabilities | $2,035,960 | $2,398,124 | | Total liabilities | $2,946,702 | $3,820,955 | | Total equity | $6,988,044 | $8,968,085 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Q3 FY2025 revenues were **$304,393**, operating loss **$3.7 million**, and net loss **$19.4 million** Statement of Operations (Three Months Ended June 30) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Total Revenues | $304,393 | $472,789 | | Gross Profit | $5,130 | $242,601 | | Loss from Operations | ($3,694,060) | ($3,306,293) | | Net (Loss) Income from Continuing Operations | ($3,647,914) | $1,883,292 | | Net (Loss) Income Attributable to Common Stockholders | ($19,445,607) | $1,879,796 | | Net (Loss) Income Per Share | ($34.00) | $1,170.48 | [Reconciliation of Non-GAAP Measures (Adjusted EBITDA)](index=8&type=section&id=CALCULATION%20AND%20RECONCILIATION%20OF%20ADJUSTED%20EBITDA) Consolidated Adjusted EBITDA loss for Q3 FY2025 was **$3.9 million**, compared to **$3.2 million** prior year Adjusted EBITDA Reconciliation (Three Months Ended June 30) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Net (Loss) Income | ($3,984,109) | $1,849,501 | | Consolidated Adjusted EBITDA (Loss) | ($3,927,551) | ($3,175,688) |